Ann: Encouraging Phase II TACTI-002 data reported at SITC 2020, page-7

On the basis of comments made by Fred that matureTACTI results warrant late stage clinical investigation:-
The $20+ million question is who pays?
Thus far we are receiving pembro (Keytruda) free of charge but all other costs are Immuteps.
Is data thus far compelling enough for Merck to buy/license efti in NSCLC and HNSCC settings and then take on all costs throught to P3 conclusion?
If not then a CR is inevitable for IMM to take on a P2b or P3 (see AIPAC).
Merck will be very aware of our predicament and suggest they are in no hurry to commit yet, as its a one horse race.
It was different in AIPAC and efti/chemo combo as chemo was generic out of IP. Looking forward to AIPAC - OS next month.
All that said, Fred also mentioned that efti should work with any PD-1/PD-L1 drug (especially beneficial in low PD-1 expression) and there are a now few competitors on Merck's tail.
Therefore latest results are building up solid data set in combo with PD-1 and it may just be an opportunity for another big pharma to come a knocking?
I hear Pfizer will be coming in to a few $billion news sales revenue soon and we are partnering with them in 'Insight' trial.....just a thought
Novartis, GSK, BMS and others will be watching too.....